华润医药(03320.HK)上半年研发支出6.6亿元 约200个创新项目
华润医药(03320.HK)公布,已涵盖心脑血管、抗肿瘤、呼吸科、儿科、神经科、抗感染、消化科、皮肤科及感冒止咳等治疗领域,今年共生产超过540种产品,其中超过300种产品进入了国家医保目录,139个产品在基药目录内。去年销售规模超过10亿港元的产品有7个,过亿港元的产品有49个。公司并累计组建了数千人的专业化销售推广团队,目前建立了与6,800多家等级医院和超过11万基层医疗机构的长期深入业务合作关系。
今年上半年公司研发支出共计6.6亿港元,按人民币计按年增加7.9%。6月底止共有各类研发创新项目约200个,其中创新药在研项目45个。公司上半年引进多个具有临床价值和市场价值的在研品种,涉及眼科、新陈代谢、抗肿瘤和胃肠道等领域,其中包括5个1类化学创新药及一个生物类似药。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.